- López-Gil, Juan Carlos
- García-Silva, Susana
- Ruiz-Cañas, Laura
- Navarro, Diego
- Palencia-Campos, Adrián
- Giráldez-Trujillo, Antonio
- Earl, Julie
- Dorado, Jorge
- Gómez-López, Gonzalo
- Monfort-Vengut, Ana
- Alcalá, Sonia
- Gaida, Matthias M.
- García-Mulero, Sandra
- Cabezas-Sainz, Pablo
- Batres-Ramos, Sandra
- Barreto, Emma
- Sánchez-Tomero, Patricia
- Vallespinós, Mireia
- Ambler, Leah
- Lin, Meng-Lay
- Aicher, Alexandra
- García García de Paredes, Ana
- Pinta, Carolina De La
- Sanjuanbenito, Alfonso
- Ruz-Caracuel, Ignacio
- Rodríguez-Garrote, Mercedes
- Guerra, Carmen
- Carrato, Alfredo
- Cárcer, Guillermo de
- Sánchez, Laura
- Nombela-Arrieta, César
- Espinet, Elisa
- Sánchez-Arévalo Lobo, Víctor J.
- Heeschen, Christopher
- Sainz, Bruno Jr.
[Objective]: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant ‘stem-like’ cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies., [Design]: We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed., [Results]: Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC., [Conclusions]: This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy., JCL-G received support from a ’la Caixa’ Foundation (ID 100010434)
fellowship (LCF/BQ/DR21/11880011) and an EMBO Scientific Exchange Fellowship
(ID 10210). AP-C was a recipient of a Juan de la Cierva Formación 2020 (FJC2020-
044220-I) grant. This study was supported by a Fero Foundation Grant (BSJr.) and
Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía
y Competitividad, Spain (BSJr.); received funding from the Beca Carmen Delgado/
Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (BSJr), a Conquer Cancer Now
Grant from the Concern Foundation (Los Angeles, CA, USA) (BSJr), a Coordinated
grant (GC16173694BARB) from the Fundación Asociación Española Contra el
Cáncer (AECC) (BSJr; AC), and FIS grants PI18/00757 and PI21/01110 (BSJr),
PI19/00514 (CG) and PI22/00492 (VJSAL); and cofinanced through Fondo Europeo
de Desarrollo Regional ’Una manera de hacer Europa’). We also acknowledge the
support from CIBERONC (CB16/12/00446) (AC) and Ayudas de Consolidación y
Estructuración de grupos from Consellería de Educación, Universidade y Formación
profesional (ED431C-2028/28) and Programa de axudas á etapa posdotoral, both
from Xunta de Galicia (LS, PCS). Projects were financed via MCIN/ AEI/FEDER
(10.13039/501100011033) (REF-PID2021-125705OB-I00 (GdC) and REF-RTI2018-
095496-B-100) (GdC), and PID2021-124520OA-I00 and RYC2020-029767 (EE),
and others including AECC (LABAE16017DECÁ, GdC and TRNSC213893ESPI, SG-M);
the Clinical Research Priority Program ’ImmunoCure’ of the University of Zurich
(CN-A), the German Research Foundation (SFB1292 Project Number 318346496,
TPQ1 and TP22), GA1818/2-3 (MMG) as well as funding from an ERC Advanced
Investigator Grant (Pa-CSC 233460, CH), the European Community’s Seventh
Framework Programme (FP7) under grant agreement n° 602783 (CAM-PaC, CH),
the Fondazione del Piemonte per l’Oncologia – IRCCS (PTCRC-Intra-2021, CH), the
Fondazione AIRC per la ricerca sul cancro (IG 2023 ID 28933, CH), the Shanghai
Municipal Education Commission (2021-01-07-00-02-E00090, CH), and the
National Science Foundation China (82130074, CH)., Peer reviewed